It has been shown that Aβ42 and tau become increasingly abnormal in CSF from SCD to progressively more severe stages of mild cognitive impairment (MCI) up to AD, but also that Aβ42 and tau biomarkers cannot differentiate between SCD and controls (reviewed in 14). This evidence concerns the gene MAPT and Cognitive impairment.